1. Trang chủ
  2. » Ngoại Ngữ

AACR 2020 Virtual Session I - Case CCC Highlights

4 5 0

Đang tải... (xem toàn văn)

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 4
Dung lượng 90,08 KB

Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này

Nội dung

Massachusetts General Hospital, Harvard Medical School., Boston, MA, South Texas Accelerated Research Therapeutics, San Antonio, TX, Columbia University-Herbert Irving Comprehensive Canc

Trang 1

American Association for Cancer Research (AACR)

Virtual Annual Meeting I Monday, April 27-Tuesday, April 28, 2020 (Case CCC Members in Bold)

Virtual Plenary Sessions

CT031 - COM701 demonstrates preliminary antitumor activity as monotherapy and in combination with nivolumab in patients with advanced solid tumors

Ryan Sullivan, Drew Rasco, Emerson Lim, Manish Sharma, Dale Shepard, Amita Patnaik, Erika Hamilton, Gini Fleming, Kyri Papadopoulos, Adam ElNaggar, Adeboye Henry Adewoye, Bartosz Chmielowski, Ecaterina Dumbrava, Dan Vaena Massachusetts General Hospital, Harvard Medical School., Boston, MA, South Texas Accelerated Research Therapeutics, San Antonio, TX, Columbia University-Herbert Irving Comprehensive Cancer Center, New York City, NY, START Midwest, Grand Rapids, MI, Cleveland Clinic Taussig Cancer

Institute, Cleveland, OH, Tennessee Oncology, PLLC and Sarah Cannon Research Institute, Nashville, TN, University of Chicago School of Medicine., Chicago, IL, University of Tennessee West Cancer Center, Memphis,

TN, Compugen USA, Inc., South San Francisco, CA, David Geffen School of Medicine at UCLA, Los Angeles, CA, The University of Texas MD Anderson Cancer Center, Houston, TX

11:45 AM - 11:55 AM

April 27, 2020, 11:40 AM - 2:00 PM; VCTPL03 - Immunotherapy Clinical Trials 1

https://www.abstractsonline.com/pp8/#!/9045/session/852

https://www.abstractsonline.com/pp8/#!/9045/presentation/10741

Session Type: Virtual Plenary Session

Track(s): Clinical Trials, Immunology

CT032 - A phase 1/2, open-label, multicenter, dose escalation and efficacy study of mRNA-2416, a lipid nanoparticle encapsulated mRNA encoding human OX40L, for intratumoral injection alone or in combination with durvalumab for patients with advanced malignancies

Antonio Jimeno, Shilpa Gupta, Ryan Sullivan, Khanh T Do, Wallace L Akerley, Ding Wang, Deanna Teoh, Kurt Schalper, Sima J Zacharek, Jing Sun, Andressa S Laino, Joshua Frederick, Honghong Zhou, William Randolph, Stephanie Pascarella, Lisa Johansen, Pamela S Cohen, ROBERT S MEEHAN Sr., Todd M Bauer University of Colorado Cancer Center, Aurora, CO, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland, OH, Massachusetts General Hospital, Boston, MA, Dana Farber Cancer Institute, Boston, MA, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, Henry Ford Hospital, Detroit, MI, University of Minnesota Medical Center, Minneapolis, MN, Yale School of Medicine, New Haven, CT, MODERNA Tx INC., CAMBRIDGE,

MA, Sarah Cannon Research Institute / Tennessee Oncology, PLLC, Nashville, TN

12:00 PM - 12:10 PM

April 27, 2020, 11:40 AM - 2:00 PM; VCTPL03 - Immunotherapy Clinical Trials 1

https://www.abstractsonline.com/pp8/#!/9045/session/852

https://www.abstractsonline.com/pp8/#!/9045/presentation/10742

Session Type: Virtual Plenary Session

Track(s): Clinical Trials, Immunology

Trang 2

CT021 - Prediction of cancer and tissue of origin in individuals with suspicion of cancer using a cell-free DNA multi-cancer early detection test

David D Thiel, Xiaoji Chen, Kathryn N Kurtzman, Jessica Yecies, Tony Wu, Quan Zhang, Hai Liu, Nan Zhang, Eric T Fung, Michael V Seiden, Minetta C Liu, Geoffrey R Oxnard, Earl Hubbell, Alexander M Aravanis, Anne-Renee Hartman, Eric A Klein Mayo Clinic Florida, Jacksonville, FL, GRAIL, Menlo Park, CA, US Oncology Research, The Woodlands, TX, Mayo Clinic Rochester, Rochester, MN, Dana Farber Cancer Institute, Boston,

MA, Cleveland Clinic, Cleveland, OH

1:25 PM - 1:35 PM

April 28, 2020, 1:20 PM - 3:20 PM; VCTPL02 - Early Detection and ctDNA

https://www.abstractsonline.com/pp8/#!/9045/presentation/10733

https://www.abstractsonline.com/pp8/#!/9045/session/848

Session Type: Virtual Plenary Session

Track(s): Clinical Trials

Virtual Minisymposia

3403 - Drugging the undruggable: Lessons learned from protein phosphatase 2A

Derek Taylor, Goutham Narla Case Western Reserve University, Cleveland, OH, University of Michigan, Ann Arbor, MI

2:50 PM - 3:00 PM

April 27, 2020, 1:30 PM - 3:30 PM; VMS.ET01.01 - Drugging Undrugged Cancer Targets

https://www.abstractsonline.com/pp8/#!/9045/session/835

https://www.abstractsonline.com/pp8/#!/9045/presentation/10545

Session Type: Virtual Minisymposium

Track(s): Experimental and Molecular Therapeutics, Drug Development

5705 - Mechanisms and therapeutic implications of hypermutation in gliomas

Mehdi Touat, Yvonne Y Li, Adam N Boynton, Liam F Spurr, Bryan Iorgulescu, Craig L Bohrson, Isidro Cortes-Ciriano, Jack E Geduldig, Kristine Pelton, Mary J Lim-Fat, Sangita Pal, Shakti H Ramkissoon, Frank Dubois, Charlotte Bellamy, Naomi Currimjee, Kenin Qian, Seth Malinowski, Aniket Shetty, Kin-Hoe Chow, Mạté Verreault, Erell Guillerm, Samy Ammari, Frédéric Beuvon, Karima Mokhtari, Agusti Alentorn, Caroline Dehais, Caroline Houillier, Florence Laigle-Donadey, Dimitri Psimaras, Alexandre Carpentier, Philippe Cornu, Laurent Capelle, Bertrand Mathon, Jill S Barnholtz-Sloan, Arnab Chakravarti, Wenya L Bi, Garrett M Frampton, Marc Sanson, Brian M Alexander, Andrew Cherniack, Patrick Y Wen, David A Reardon, Aurelien Marabelle, Peter J Park, Ahmed Idbaih, Rameen Beroukhim, Pratiti Bandopadhayay, Franck Bielle, Keith L Ligon Dana-Farber Cancer Institute, Boston, MA, Dana-Dana-Farber Cancer Institute, Boston, MA, Broad Institute of MIT and Harvard, Cambridge, MA, MA, Dana-Farber Cancer Institute, Boston, MA, Harvard Medical School, Boston,

MA, European Molecular European Bioinformatics Institute, Wellcome Genome Campus, HInxton, United Kingdom, Broad Institute of MIT and Harvard, Cambridge, MA, Foundation Medicine Inc, Cambridge, MA, Dana-Farber Cancer Institute, Boston, MA, Sorbonne Université, Inserm, Paris, France, Hơpitaux

Universitaires La Pitié Salpêtrière, Paris, France, Gustave Roussy, Villejuif, France, Université Paris Descartes, Hơpital Cochin, Paris, France, Sorbonne Université, Hơpitaux Universitaires La Pitié Salpêtrière, Paris, France, Case Western Reserve University School of Medicine, Cleveland, OH, Arthur G James Hospital/Ohio State Comprehensive Cancer Center, Cleveland, OH, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, Foundation Medicine, Boston, MA, Sorbonne Universite, France, Dana Farber Cancer Institute, Boston, MA, Gustave Roussy, Paris, France, Harvard Medical School, Boston, MA, Sorbonne Université, France, Sorbonne Université, Paris, France

Trang 3

4:40 PM - 4:50 PM

April 28, 2020, 3:50 PM - 5:35 PM; VMS.MCB09.01 - Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease

https://www.abstractsonline.com/pp8/#!/9045/session/838

https://www.abstractsonline.com/pp8/#!/9045/presentation/10570

Session Type: Virtual Minisymposium

Track(s): Molecular and Cellular Biology/Genetics

Virtual Poster Sessions

CT134 - Tilsotolimod engages the TLR9 pathway to promote antigen presentation and Type-I IFN signaling

in solid tumors

Hani M Babiker, Vivek Subbiah, Asim Ali, Alain Algazi, Jacob Schachter, Michal Lotem, Corinne Maurice-Dror, Daniel Hendler, Shah Rahimian, Hans Minderman, Cara Haymaker, Chantale Bernatchez, Ravi Murthy, Rolf Hultsch, Nadia Caplan, Gregory Woodhead, Charles Hennemeyer, Sri Chunduru, Peter Anderson, Adi Diab, Erkut Borazanci, Igor Puzanov University of Arizona Cancer Center, Tucson, AZ, University of Texas MD Anderson Cancer Center, Houston, TX, Saint Luke’s University Health Network, Easton, PA, University of California, San Francisco, CA, Sheba Medical Center, Tel HaShomer, Israel, Hadassah Hebrew University Medical Center, Jerusalem, Israel, Rambam Health, Haifa, Israel, Rabin Medical Center, Petach Tikva, Israel, Idera Pharmaceuticals, Exton, PA, Roswell Park Comprehensive Cancer Center, Buffalo, NY, HonorHealth, Scottsdale, AZ, Cleveland Clinic, Cleveland, OH

9:00 AM - 6:00 PM

April 27, 2020, 9:00 AM - 6:00 PM; VPO.CT01 - Phase I Clinical Trials

https://www.abstractsonline.com/pp8/#!/9045/session/842

Session Type: Virtual Poster Session

Track(s): Clinical Trials

CT236 - A phase 1b, multicenter, randomized, blinded, placebo-controlled study to evaluate the efficacy of guselkumab in subjects with familial adenomatous polyposis

Eduardo Vilar-Sanchez, Carol Burke, Marcia R Cruz Correa, Evelien Dekker, William M Grady, Philippe Grandval, Bryson W Katona, Xavier Llor, Douglas L Riegert-Johnson, Jean-Christophe Saurin, Peter Stanich, Daniel A Sussman, David Weinberg, Edward F Attiyeh, Devanand Joseph, Kelly Raybold, Gary V Borzillo, Thomas J Prior, Michael Smith, Hong Xie, Kurtis E Bachman, Jeffrey R Infante, Niloy Jewel Samadder MD Anderson Cancer Center, Houston, TX, Cleveland Clinic, Cleveland, OH, University of Puerto Rico School of Medicine, San Juan, PR, Amsterdam University Medical Centers, Amsterdam, Netherlands, Fred Hutchinson Cancer Research Center and University of Washington, School of Medicine, Seattle, WA, Assistance Publique Hôpitaux de Marseille, Marseille, France, University of Pennsylvania Perelman School of Medicine,

Philadelphia, PA, Department of Medicine and Cancer Center, Yale University, New Haven, CT, Mayo Clinic, Jacksonville, FL, Hôpital Edouard Herriot, Lyon, France, Ohio State University Wexner Medical Center,

Columbus, OH, University of Miami Miller School of Medicine, Miami, FL, Fox Chase Cancer Center,

Philadelphia, PA, Janssen Research & Development, LLC, Spring House, PA, Mayo Clinic, Phoenix, AZ

9:00 AM - 6:00 PM

April 27, 2020, 9:00 AM - 6:00 PM; VPO.CT07.01 - Phase I Trials in Progress

https://www.abstractsonline.com/pp8/#!/9045/presentation/10664

https://www.abstractsonline.com/pp8/#!/9045/session/845

Session Type: Virtual Poster Session

Track(s): Clinical Trials

Trang 4

CT281 - Pivotal study of the LUM Imaging System for assisting intraoperative detection of residual cancer in the tumor bed of female patients with breast cancer

Jorge Ferrer, David Carr, Irene Wapnir, Kelly Hunt, Peter Blumencranz, Nayana Dekhne, Daleela Dodge, Donna Lynn Dyess, Shelley Hwang, Stephanie Valente, Lynne Clark, Beth-Ann Lesnikoski, Anees Chagpar, Paticia Clark, Marie Catherine Lee, Brian Schlossberg, Sean Madden, Livia Gjylameti, Manna Chang, Kate Smith, Barbara Smith Lumicell, Inc, Newton, MA, Novant Health, Winston-Salem, NC, Stanford Cancer Institute, Stanford, CA, The University of Texas M.D Anderson Cancer Center, Houston, TX, The

Comprehensive Breast Care Center of Tampa Bay (BayCare), Clearwater, FL, Beaumont Health System, Royal Oak, MI, Penn State Milton S Hershey Medical Center, Hershey, PA, Mitchell Cancer Institute-University of South Alabama, Mobile, AL, Duke University Medical Center, Durham, NC, Cleveland Clinic Foundation, Cleveland, OH, CHI Franciscan Research Center, Tacoma, WA, Baptist MD Anderson Cancer Center,

Jacksonville, FL, Yale University-Smilow Cancer Center, New Haven, CT, HonorHealth Research Institute, Scottsdale, AZ, Moffitt Cancer Center, Tampa, FL, Massachusetts General Hospital, Boston, MA

9:00 AM - 6:00 PM

April 27, 2020, 9:00 AM - 6:00 PM; VPO.CT07.03 - Phase III Trials in Progress

https://www.abstractsonline.com/pp8/#!/9045/session/847

https://www.abstractsonline.com/pp8/#!/9045/presentation/10721

Session Type: Virtual Poster Session

Track(s): Clinical Trials

CT291 - The PATHFINDER Study: Assessment of the implementation of an investigational multi-cancer early detection test into clinical practice

Lincoln Nadauld, Charles H McDonnell III, Minetta C Liu, Eric Klein, Tomasz M Beer, Deborah Schrag,

Andrew G Hudnut, Richard Whittington, Bruce Taylor, Joanna Tierney, Catherine Marinac, Jafi Lipson,

Margarita Lopatin, Karen C Chung, Eric Fung, Anne-Renee Hartman, Geoffrey R Oxnard Intermountain Healthcare, St George, UT, Sutter Health, Sacramento, CA, Mayo Clinic, Rochester, MN, Cleveland Clinic, Cleveland, OH, Oregon Health & Science University Knight Cancer Institute, Portland, OR, Dana-Farber Cancer Institute, Boston, MA, Sutter Health, Sacremento, CA, Intermountain Healthcare, Salt Lake City, UT, GRAIL, Menlo Park, CA

9:00 AM - 6:00 PM

April 27, 2020, 9:00 AM - 6:00 PM; VPO.CT07.03 - Phase III Trials in Progress

https://www.abstractsonline.com/pp8/#!/9045/session/847

https://www.abstractsonline.com/pp8/#!/9045/presentation/10731

Session Type: Virtual Poster Session

Track(s): Clinical Trials

Ngày đăng: 02/11/2022, 00:51

w